A clinical study of TA-46 in children with achondroplasia
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs TA-46 (Primary)
- Indications Achondroplasia
- Focus Therapeutic Use
- 01 Jul 2019 According to a Pfizer media release, the company has acquired Therachon Holding AG.
- 27 Aug 2018 New trial record
- 09 Aug 2018 According to a Therachon media release, this study is expected to start in 2019.